{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:04:25Z","timestamp":1790863465380,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1007\/s11912-008-0008-9","type":"journal-article","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T21:08:41Z","timestamp":1202332121000},"page":"47-53","source":"Crossref","is-referenced-by-count":12,"title":["The clinical management of BRCA1 and BRCA2 mutation carriers"],"prefix":"10.1007","volume":"10","author":[{"given":"Anthony P.","family":"Gulati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Domchek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,2,7]]},"reference":[{"key":"8_CR1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"M.C. King","year":"2003","unstructured":"King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302:643\u2013646.","journal-title":"Science"},{"key":"8_CR2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/jmg.2004.024133","volume":"42","author":"A.C. Antoniou","year":"2005","unstructured":"Antoniou AC, Pharoah PD, Narod S, et al.: Breast and ovarian cancer risks to carriers of the BRCA 5382insC and 185delAG and BRCA2 6171delT mutations: a combined analysis of 22 population based studies. J Med Genet 2005, 42:602\u2013603.","journal-title":"J Med Genet"},{"key":"8_CR3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1525-1438.2006.00480.x","volume":"16","author":"K.N. Gaarenstroom","year":"2006","unstructured":"Gaarenstroom KN, van der Hiel B, Tollenaar RA, et al.: Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 2006, 16:54\u201359.","journal-title":"Int J Gynecol Cancer"},{"key":"8_CR4","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/sj.bjc.6603015","volume":"94","author":"A.L. Oei","year":"2006","unstructured":"Oei AL, Massuger LF, Bulten J, et al.: Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 2006, 94:814\u2013819.","journal-title":"Br J Cancer"},{"key":"8_CR5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ygyno.2005.08.038","volume":"100","author":"R.I. Olivier","year":"2006","unstructured":"Olivier RI, Lubsen-Brandsma MA, Verhoef S, et al.: CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006, 100:20\u201326.","journal-title":"Gynecol Oncol"},{"key":"8_CR6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJM199808133390702","volume":"339","author":"S.A. Narod","year":"1998","unstructured":"Narod SA, Risch H, Moslehi R, et al.: Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998, 339:424\u2013428.","journal-title":"N Engl J Med"},{"key":"8_CR7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1470-2045(06)70983-4","volume":"8","author":"J.R. McLaughlin","year":"2007","unstructured":"McLaughlin JR, Risch HA, Lubinski J, et al.: Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007, 8:26\u201334.","journal-title":"Lancet Oncol"},{"key":"8_CR8","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1038\/sj.bjc.6602239","volume":"91","author":"A.S. Whittemore","year":"2004","unstructured":"Whittemore AS, Balise RR, Pharoah PD, et al.: Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 2004, 91:1911\u20131915.","journal-title":"Br J Cancer"},{"key":"8_CR9","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/jnci\/94.23.1773","volume":"94","author":"S.A. Narod","year":"2002","unstructured":"Narod SA, Dube MP, Klijn J, et al.: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002, 94:1773\u20131779.","journal-title":"J Natl Cancer Inst"},{"key":"8_CR10","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1158\/1055-9965.EPI-06-0258","volume":"15","author":"R.W. Haile","year":"2006","unstructured":"Haile RW, Thomas DC, McGuire V, et al.: BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 2006, 15:1863\u20131870.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"8_CR11","doi-asserted-by":"crossref","unstructured":"Brohet RM, Goldgar DE, Easton DF, et al.: Oral contraceptives and breast cancer risk in the International BRCA1\/2 Carrier Cohort Study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 2007, [Epub ahead of print].","DOI":"10.1200\/JCO.2007.11.1179"},{"key":"8_CR12","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","volume":"346","author":"T.R. Rebbeck","year":"2002","unstructured":"Rebbeck TR, Lynch HT, Neuhausen SL, et al.: Prophylactic oophorectomy in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2002, 346:1616\u20131622.","journal-title":"N Engl J Med"},{"key":"8_CR13","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","volume":"346","author":"N.D. Kauff","year":"2002","unstructured":"Kauff ND, Satagopan JM, Robson ME, et al.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002, 346:1609\u20131615.","journal-title":"N Engl J Med"},{"key":"8_CR14","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/95.14.1072","volume":"95","author":"J.L. Rutter","year":"2003","unstructured":"Rutter JL, Wacholder S, Chetrit A, et al.: Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 2003, 95:1072\u20131078.","journal-title":"J Natl Cancer Inst"},{"key":"8_CR15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(06)70585-X","volume":"7","author":"S.M. Domchek","year":"2006","unstructured":"Domchek SM, Friebel TM, Neuhausen SL, et al.: Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006, 7:223\u2013229.","journal-title":"Lancet Oncol"},{"key":"8_CR16","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","volume":"23","author":"A. Eisen","year":"2005","unstructured":"Eisen A, Lubinski J, Klijn J, et al.: Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005, 23:7491\u20137496.","journal-title":"J Clin Oncol"},{"key":"8_CR17","doi-asserted-by":"crossref","first-page":"8629","DOI":"10.1200\/JCO.2005.02.9199","volume":"23","author":"J.L. Kramer","year":"2005","unstructured":"Kramer JL, Velazquez IA, Chen BE, et al.: Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 2005, 23:8629\u20138635.","journal-title":"J Clin Oncol"},{"key":"8_CR18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","volume":"296","author":"A. Finch","year":"2006","unstructured":"Finch A, Beiner M, Lubinski J, et al.: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006, 296:185\u2013192.","journal-title":"JAMA"},{"key":"8_CR19","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1200\/JCO.2000.18.14.2728","volume":"18","author":"K. Lu","year":"2000","unstructured":"Lu K, Garber JE, Cramer DW, et al.: Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000, 18:2728\u20132732.","journal-title":"J Clin Oncol"},{"key":"8_CR20","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","volume":"23","author":"T.R. Rebbeck","year":"2005","unstructured":"Rebbeck TR, Friebel T, Wagner T, et al.: Effect of short term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2005, 23:7804\u20137810.","journal-title":"J Clin Oncol"},{"key":"8_CR21","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"G.L. Anderson","year":"2004","unstructured":"Anderson GL, Limacher M, Assaf AR, et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized control trial. JAMA 2004, 291:1701\u20131712.","journal-title":"JAMA"},{"key":"8_CR22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"J.E. Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial. JAMA 2002, 288:321\u2013333.","journal-title":"JAMA"},{"key":"8_CR23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa031759","volume":"351","author":"M. Kriege","year":"2004","unstructured":"Kriege M, Brekelmans CT, Boetes C, et al.: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351:427\u2013437.","journal-title":"N Engl J Med"},{"key":"8_CR24","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.292.11.1317","volume":"292","author":"E. Warner","year":"2004","unstructured":"Warner E, Plewes DB, Hill KA, et al.: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004, 292:1317\u20131325.","journal-title":"JAMA"},{"key":"8_CR25","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/S0140-6736(05)66646-9","volume":"365","author":"M.O. Leach","year":"2005","unstructured":"Leach MO, Boggis, CR, Dixon AK, et al.: Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365:1769\u20131778.","journal-title":"Lancet"},{"key":"8_CR26","doi-asserted-by":"crossref","first-page":"5864","DOI":"10.1038\/sj.onc.1209874","volume":"25","author":"K. Gudmundsdottir","year":"2006","unstructured":"Gudmundsdottir K, Ashworth A: The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006, 25:5864\u20135874.","journal-title":"Oncogene"},{"key":"8_CR27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/bcr970","volume":"7","author":"C.M. Ronkers","year":"2005","unstructured":"Ronkers CM, Erdmann CA, Land CE: Radiation and breast cancer: a review of current evidence. Breast Cancer Res 2005, 7:21\u201332.","journal-title":"Breast Cancer Res"},{"key":"8_CR28","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1667\/RR3082","volume":"160","author":"C.E. Land","year":"2003","unstructured":"Land CE, Tokunaga M, Koyoma K, et al.: Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950\u20131990. Radiat Res 2003, 160:707\u2013717.","journal-title":"Radiat Res"},{"key":"8_CR29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1470-2045(06)70624-6","volume":"7","author":"S.A. Narod","year":"2006","unstructured":"Narod SA, Lubinski J, Ghadirian P, et al.: Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol 2006, 7:402\u2013406.","journal-title":"Lancet Oncol"},{"key":"8_CR30","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1158\/1055-9965.EPI-06-0176","volume":"15","author":"D. Goldfrank","year":"2006","unstructured":"Goldfrank D, Chuai S, Bernstein J, et al.: Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. Cancer Epidemiol Biomarkers Prev 2006, 15:2311\u20132313.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"8_CR31","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.2005.03.3126","volume":"24","author":"N. Andrieu","year":"2006","unstructured":"Andrieu N, Easton D, Chang-Claude J, et al.: Effect of chest x-rays on the risk of breast cancer among BRCA1\/2 mutation carriers in the international BRCA1\/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators\u2019 Group. J Clin Oncol 2006, 24:3328\u20133330.","journal-title":"J Clin Oncol"},{"key":"8_CR32","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ijc.22668","volume":"121","author":"E. John","year":"2007","unstructured":"John E, Phipps A, Knight J, et al.: Medical radiation exposure and breast cancer risk: findings from the breast cancer family registry. Int J Cancer 2007, 121:386\u2013394.","journal-title":"Int J Cancer"},{"key":"8_CR33","doi-asserted-by":"crossref","unstructured":"Kauff ND, Domchek SM, Friebel TM, et al.: Multi-center prospective analysis of risk-reducing salpingo-oophorectomy to prevent BRCA-associated breast and ovarian cancer. J Clin Oncol 2007, [In press].","DOI":"10.1200\/jco.2006.24.18_suppl.1003"},{"key":"8_CR34","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","volume":"356","author":"S.A. Narod","year":"2000","unstructured":"Narod SA, Brunet JS, Ghadirian P, et al.: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000, 356:1876\u20131881.","journal-title":"Lancet"},{"key":"8_CR35","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/ijc.21536","volume":"118","author":"J. Grunwald","year":"2006","unstructured":"Grunwald J, Tung N, Foulkes WD: Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006, 118:2281\u20132284.","journal-title":"Int J Cancer"},{"key":"8_CR36","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B. Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wicherham DL, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371\u20131388.","journal-title":"J Natl Cancer Inst"},{"key":"8_CR37","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","volume":"286","author":"M.C. King","year":"2001","unstructured":"King MC, Wieand S, Hale K, et al.: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001, 286:2251\u20132256.","journal-title":"JAMA"},{"key":"8_CR38","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"V.G. Vogel","year":"2006","unstructured":"Vogel VG, Constantino JP, Wickerham DL, et al.: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727\u20132741.","journal-title":"JAMA"},{"key":"8_CR39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","volume":"240","author":"L.C. Hartmann","year":"1999","unstructured":"Hartmann LC, Schaid DJ, Woods JE, et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999, 240:77\u201384.","journal-title":"N Engl J Med"},{"key":"8_CR40","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","volume":"93","author":"L.C. Hartmann","year":"2001","unstructured":"Hartmann LC, Sellers TA, Schaid DJ, et al.: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001, 93:1633\u20131637.","journal-title":"J Natl Cancer Inst"},{"key":"8_CR41","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1200\/JCO.2004.04.188","volume":"22","author":"T.R. Rebbeck","year":"2004","unstructured":"Rebbeck TR, Friebel T, Lynch HT, et al.: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004, 22:981\u2013983.","journal-title":"J Clin Oncol"},{"key":"8_CR42","first-page":"2981","volume":"10","author":"T. Walsh","year":"2006","unstructured":"Walsh T, Casadei S, Hale Coats K, et al.: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006, 10:2981\u20132921.","journal-title":"JAMA"},{"key":"8_CR43","unstructured":"Genetic testing for hereditary cancer syndromes resource guide. Myriad Genetic Laboratories, Inc. website. http:\/\/www.myriadresourceguide.com\/bracanal\/guidelines.htm . Accessed October 16, 2007."},{"key":"8_CR44","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2000.18.19.3360","volume":"18","author":"L.J. Pierce","year":"2000","unstructured":"Pierce LJ, Strawderman M, Narod SA, et al.: Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1\/2 mutations. J Clin Oncol 2000, 18;3360\u20133369.","journal-title":"J Clin Oncol"},{"key":"8_CR45","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2005.02.7888","volume":"24","author":"L.J. Pierce","year":"2006","unstructured":"Pierce LJ, Levin AM, Rebbeck TR, et al.: Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1\/2-associated stage I\/II breast cancer. J Clin Oncol 2006, 24:2437\u20132443.","journal-title":"J Clin Oncol"},{"key":"8_CR46","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1200\/JCO.2004.04.086","volume":"22","author":"M.D. Schwartz","year":"2004","unstructured":"Schwartz MD, Lerman C, Brogan B, et al.: Impact of BRCA1\/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004, 22:1823\u20131829.","journal-title":"J Clin Oncol"},{"key":"8_CR47","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1200\/JCO.2002.09.023","volume":"20","author":"S.R. Lakhani","year":"2002","unstructured":"Lakhani SR, Van De Vijver MJ, Jacquemier J, et al.: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002, 20:2310\u20132318.","journal-title":"J Clin Oncol"},{"key":"8_CR48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa070608","volume":"357","author":"G. Rennert","year":"2007","unstructured":"Rennert G, Bisland-Naggan S, Barnett-Griness O, et al.: Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007, 357:115\u2013123.","journal-title":"N Engl J Med"},{"key":"8_CR49","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/cncr.11310","volume":"97","author":"I. Cass","year":"2003","unstructured":"Cass I, Baldwin RL, Varkey T, et al.: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003, 97:2187\u20132195.","journal-title":"Cancer"},{"key":"8_CR50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","volume":"108","author":"A.R. Venkitaraman","year":"2002","unstructured":"Venkitaraman AR: Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002, 108:171\u2013182.","journal-title":"Cell"},{"key":"8_CR51","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/jnci\/djh312","volume":"96","author":"R.D. Kennedy","year":"2004","unstructured":"Kennedy RD, Quinn JE, Mullan PB, et al.: The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004, 96:1659\u20131668.","journal-title":"J Natl Cancer Inst"},{"key":"8_CR52","first-page":"145S","volume":"25","author":"T.A. Yap","year":"2007","unstructured":"Yap TA, Boss DS, Fong PC, et al.: Phase I study of AZD2281 (KU-0059436), a poly ADP-ribose polymerase (PARP) inhibitor in cancer patients, including BRCA1\/2 mutation carriers. J Clin Oncol 2007, 25:145S.","journal-title":"J Clin Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-008-0008-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-008-0008-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-008-0008-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T19:54:01Z","timestamp":1588362841000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-008-0008-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["8"],"URL":"https:\/\/doi.org\/10.1007\/s11912-008-0008-9","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}